NASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $33.92 +0.62 (+1.86%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$33.03▼$33.9550-Day Range$28.81▼$34.7152-Week Range$18.61▼$39.26Volume272,634 shsAverage Volume386,242 shsMarket Capitalization$1.93 billionP/E Ratio14.68Dividend YieldN/APrice Target$41.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Harmony Biosciences alerts: Email Address Harmony Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside22.8% Upside$41.67 Price TargetShort InterestBearish26.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth71.78%From $2.02 to $3.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.69 out of 5 starsMedical Sector265th out of 936 stocksPharmaceutical Preparations Industry121st out of 436 stocks 2.3 Analyst's Opinion Consensus RatingHarmony Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 7 buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageHarmony Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Harmony Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted26.30% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.Change versus previous monthShort interest in Harmony Biosciences has recently decreased by 3.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HRMY. Previous Next 3.2 News and Social Media Coverage News SentimentHarmony Biosciences has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Harmony Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for HRMY on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows6 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders30.80% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 71.78% in the coming year, from $2.02 to $3.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 14.68, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 14.68, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.32.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.72. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 4.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Harmony Biosciences Stock (NASDAQ:HRMY)Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Read More HRMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HRMY Stock News HeadlinesJuly 24 at 1:53 PM | finance.yahoo.comHarmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock Is Going Strong: Is the Market Following Fundamentals?July 24 at 8:53 AM | finance.yahoo.comHRMY Aug 2024 20.000 put (HRMY240816P00020000)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 23 at 8:05 AM | prnewswire.comHARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024July 1, 2024 | investorplace.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsJune 25, 2024 | prnewswire.comHARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)June 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024June 24, 2024 | prnewswire.comHARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSYJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 5, 2024 | prnewswire.comHARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1May 28, 2024 | prnewswire.comHARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCEMay 6, 2024 | msn.comHarmony Biosciences Expands into Rare Epilepsy Market with Epygenix Therapeutics AcquisitionMay 4, 2024 | finance.yahoo.comResults: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsMay 3, 2024 | finance.yahoo.comHarmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats ExpectationsMay 2, 2024 | markets.businessinsider.comLooking for a Growth Stock? 3 Reasons Why Harmony Biosciences is a Solid ChoiceMay 2, 2024 | msn.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comHarmony Biosciences Holdings Inc (HRMY) Q1 2024 Earnings Call Transcript Highlights: Strong ...May 1, 2024 | msn.comEasterly Government Properties, Inc. (NYSE:DEA) Q1 2024 Earnings Call TranscriptSee More Headlines Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CUSIPN/A CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$41.67 High Stock Price Target$59.00 Low Stock Price Target$27.00 Potential Upside/Downside+22.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$2.31 Trailing P/E Ratio14.68 Forward P/E Ratio16.79 P/E Growth0.72Net Income$128.85 million Net Margins22.30% Pretax Margin30.35% Return on Equity28.26% Return on Assets17.23% Debt Debt-to-Equity Ratio0.34 Current Ratio3.11 Quick Ratio3.07 Sales & Book Value Annual Sales$582.02 million Price / Sales3.31 Cash Flow$2.70 per share Price / Cash Flow12.58 Book Value$7.97 per share Price / Book4.26Miscellaneous Outstanding Shares56,790,000Free Float39,300,000Market Cap$1.93 billion OptionableOptionable Beta0.72 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Jeffrey S. Aronin (Age 56)Founder & Non-Executive Chairman Comp: $185.67kDr. Jeffrey M. Dayno M.D. (Age 67)President, CEO & Director Comp: $1.26MMr. Sandip S. Kapadia CPA (Age 54)M.B.A., Executive VP, Chief Administrative Officer & CFO Comp: $813.52kMr. David BradshawHead of Technical OperationsLuis SanayHead of Investor RelationsMr. Christian UlrichGeneral Counsel & Corporate SecretaryMs. Tricia GloverChief Compliance OfficerMs. Audrey Murphy SPHRVice Presidet of Human ResourcesMs. Cate McCanlessHead of Corporate Affairs & Public PolicyMs. Kelli WrightSenior Manager of Patient Advocacy & Harmony BiosciencesMore ExecutivesKey CompetitorsTaro Pharmaceutical IndustriesNYSE:TAROAimmune TherapeuticsNASDAQ:AIMTRa PharmaceuticalsNASDAQ:RARXXencorNASDAQ:XNCROPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 18,820 shares on 7/26/2024Ownership: 0.475%Allspring Global Investments Holdings LLCSold 2,970 shares on 7/26/2024Ownership: 0.057%Summit Global InvestmentsBought 807 shares on 7/22/2024Ownership: 0.036%Hennion & Walsh Asset Management Inc.Bought 30,638 shares on 7/20/2024Ownership: 0.079%Hedeker Wealth LLCSold 5,598 shares on 7/19/2024Ownership: 0.128%View All Insider TransactionsView All Institutional Transactions HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $32.30 at the beginning of the year. Since then, HRMY stock has increased by 5.0% and is now trading at $33.92. View the best growth stocks for 2024 here. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) issued its earnings results on Tuesday, April, 30th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.07. Harmony Biosciences's revenue was up 29.8% on a year-over-year basis. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an IPO on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' top institutional investors include Bank of New York Mellon Corp (0.48%), Hedeker Wealth LLC (0.13%), Hennion & Walsh Asset Management Inc. (0.08%) and Allspring Global Investments Holdings LLC (0.06%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR) and Commercial Metals (CMC). This page (NASDAQ:HRMY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
